BLA 761367 · Csl Behring LLC
Andembry
Garadacimab-Gxii · Subcutaneous
NovelOrphanCDER novel approval, Jun 16, 2025: To prevent attacks of hereditary angioedema
Last checked: Nov 20, 2026Latest source record: Jun 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jun 16, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
3 Phase 3, 0 recruiting
FAERS reports
767
597 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2025.
ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ANDEMBRY is an activated Factor XII (FXIIa) inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ( 1 )
Mechanism: Garadacimab-gxii is an inhibitor of activated FXII that binds to the catalytic domain of activated Factor XII (FXIIa and βFXIIa) and inhibits its catalytic activity. FXII is the first factor activated in the contact activation pathway and initiates the inflammatory bradykinin-producing kallikrein-kinin system. The inhibition of FXIIa decreases the activation of prekallikrein to kallikrein and the generation of bradykinin, which is associated with inflammation and swelling in HAE attacks, thus reducing the cascade of events leading to an HAE attack.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ANDEMBRY · GARADACIMAB-GXII 200MG/1.2ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Garadacimab" as an intervention, any sponsor and status, largest first.
- Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksPivotal-lookingCompleted
CSL BehringIndustry
NCT04739059 · 171 participants · Start Mar 29, 2021 · Primary completion Nov 21, 2025
Drug: CSL312 · For: Hereditary Angioedema
Sites: Birmingham, Alabama; Litchfield Park, Arizona; Scottsdale, Arizona · 44 sites in all
- Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)Pivotal-lookingCompleted
CSL BehringIndustry
NCT04409509 · 124 participants · Start Jul 1, 2020 · Primary completion Jan 12, 2021
Drug: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody; Placebo · For: Coronavirus Disease 2019 (COVID-19)
Sites: Bradenton, Florida; St. Petersburg, Florida; Mason City, Iowa · 14 sites in all
- Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisCompleted
CSL BehringIndustry
NCT05130970 · 81 participants · Start Feb 3, 2022 · Primary completion Jan 2, 2024
Drug: Garadacimab; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Huntington Beach, California · 47 sites in all
- CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema AttacksPivotal-lookingCompleted
CSL BehringIndustry
NCT04656418 · 64 participants · Start Jan 27, 2021 · Primary completion Jun 7, 2022
Drug: CSL312; Placebo · For: Hereditary Angioedema
Sites: Birmingham, Alabama; Scottsdale, Arizona; Santa Monica, California · 28 sites in all
- A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian AdultsCompleted
CSL BehringIndustry
NCT04580654 · 38 participants · Start Oct 29, 2020 · Primary completion May 7, 2021
Drug: CSL312 · For: Healthy Volunteers
Sites: Anaheim, California
- CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaPivotal-lookingCompleted
CSL BehringIndustry
NCT05819775 · 22 participants · Start May 30, 2023 · Primary completion Nov 19, 2025
Drug: CSL312 · For: Hereditary Angioedema (HAE)
Sites: Litchfield Park, Arizona; Scottsdale, Arizona; Orange, California · 13 sites in all
- Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCompleted
CSL BehringIndustry
NCT06806657 · 18 participants · Start Apr 28, 2025 · Primary completion Jun 29, 2026
Drug: Garadacimab · For: Hereditary Angioedema
Sites: Litchfield Park, Arizona; Bentonville, Arkansas; Orange, California · 11 sites in all
CSL BehringIndustry
NCT04281524 · 0 participants · Start Mar 2020 · Primary completion Aug 2021
Drug: CSL312; Placebo · For: PICC-associated Thrombosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hereditary angioedema498
- drug ineffective93
- product dose omission issue83
- stress68
- product use issue60
- weight decreased48
- fatigue43
- therapy interrupted43
- hospitalisation42
- insurance issue42
- weight increased42
- pain38
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 25 |
| 2025 | 223 |
| 2026 | 507 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema.
Walsh S, Bartlett M, Salvo-Halloran EM, et al. · Drugs R D 2025 · Network Meta-Analysis, Systematic Review
- Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
Reshef A, Hsu C, Katelaris CH, et al. · Allergy 2025 · Clinical Trial, Phase III, Multicenter Study
- Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.
Guilarte M, Lumry WR, Magerl M, et al. · Allergy Asthma Proc 2025 · Clinical Trial, Phase III
- Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ, Reshef A, Li HH, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Craig TJ, Levy DS, Reshef A, et al. · Lancet Haematol 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.
Cohn DM, Reshef A, Staubach P, et al. · J Allergy Clin Immunol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Csl Behring LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.